Overview

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

Status:
Terminated
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
Phase:
Phase 2
Details
Lead Sponsor:
Georgetown University
Treatments:
Bevacizumab
Trifluridine